Search clinical trials for: GC101

Total 114 results

GeneCradle Inc

Recruiting

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients

SMA II

China
GeneCradle Inc

Recruiting

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients

Spinal Muscular Atrophy

China
Shanghai Juncell Therapeutics

Recruiting

A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002) (MIZAR-002)

Melanoma | Efficacy | Adverse Drug Event | Safety | Tumor Infiltrating Lymphocytes

China
Graviton Bioscience Corporation

Completed

Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects

Phase 1

United States
GeneCradle Inc

Recruiting

Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug

Pompe Disease (Late-onset)

China
GeneCradle Inc

Recruiting

Evaluation of the Safety and Efficacy of Infantile-onset Pompe Disease Gene Therapy Drug

Pompe Disease Infantile-Onset

China
Grit Biotechnology

Recruiting

GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors

Solid Tumors, Adult

China
Grit Biotechnology

Recruiting

GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors

Adult

China
Glia, LLC

Completed

Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101

Ocular Surface Disease

United States
Seventh Medical Center of PLA General Hospital
GeneCradle Therapeutics, Inc

Recruiting

Clinical Exploration of Adeno-associated Virus (AAV) Expressing Human Acid Alpha- Glucosidase (GAA) Gene Therapy for Patients With Infantile-onset Pompe Disease

Infantile-onset Pompe Disease

China
Xoc Pharmaceuticals

Active, not recruiting

Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of XC101-D13H in Healthy Adult Subjects

Migraine

United States
OriCell Therapeutics Co., Ltd.

Recruiting

Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC

Hepatocellular Carcinoma

China
BioGenCell Ltd.
Rabin Medical Center; Laniado Hospital

Recruiting

BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI) (EnEPC-CLI)

Peripheral Arterial Disease | Peripheral Vascular Disease | Critical Limb Ischemia

United States, Israel
LYSOGENE

Terminated

A Safety and Efficacy Study of LYS-GM101 Gene Therapy in Patients With GM1 Gangliosidosis

GM1 Gangliosidosis

United Kingdom, United States, France
University of KwaZulu
King's College London; Department for International Development, United Kingdom and other collaborators

Completed

Strengthening Mental Health Care in Chronic Care Patients With Hypertension. A Cluster Randomised Control Trial

Depression | Hypertension

South Africa
Nantes University Hospital
Roche Pharma AG; Janssen, LP

Active, not recruiting

A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients (OAsIs)

Mantle Cell Lymphoma

France, United Kingdom
University of California, San Diego
Pharmacyclics LLC.

Active, not recruiting

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

Chronic Lymphocytic Leukemia

United States
Genentech, Inc.

Completed

A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)

Lymphocytic Leukemia, Chronic

United States
Hoffmann-La Roche

Completed

A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma

China
Polish Lymphoma Research Group
Roche Pharma AG

Terminated

Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse (OPERA-PLRG10)

Mantle Cell Lymphoma

Poland
Christian Buske
Roche Pharma AG; University of Ulm; Zentrum für Klinische Studien Ulm; X-act Cologne... and other collaborators

Active, not recruiting

Obinutuzumab in Marginal Zone Lymphoma

Marginal Zone Lymphoma

Germany
Hoffmann-La Roche

Completed

A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)

Lymphoma

France, Germany
Fondazione Italiana Linfomi ONLUS

Terminated

GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma (FIL_GAEL)

CD20 Positive Diffuse Large B-cell Lymphoma | Elderly Unfit Patients

Italy
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Not yet recruiting

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Follicular Lymphoma | Tumor

United States
Reid Merryman, MD
Genentech, Inc.

Recruiting

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma | Indolent Non-hodgkin Lymphoma

United States
University of California, San Diego
Genentech, Inc.

Active, not recruiting

A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP) (GA101 & HDMP)

CLL

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Eosinophilic Asthma

United States, Australia, Belgium, Chile, Colombia, Czechia, Denmark, Hungary, Israel, Malaysia, New Zealand, Philippines, Poland, Russian Federation, South Africa, Sweden, Thailand
Genentech, Inc.
AbbVie (prior sponsor, Abbott)

Completed

A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

United States, United Kingdom
Grit Biotechnology

Not yet recruiting

Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

Adult

China
AbbVie
F. Hoffmann-La Roche Ltd; German CLL Study Group (GCLLSG); Dana-Farber Cancer...

Recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) (ReVenG)

Chronic Lymphocytic Leukemia (CLL)

United States, Australia, Austria, Bulgaria, Germany, Italy, Spain, Israel, Brazil, Romania
Hoffmann-La Roche

Recruiting

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Belgium, Australia, Denmark, Spain, Taiwan, France, Italy, United States, Canada, Czechia, New Zealand, Poland, Finland
Gilead Sciences
German CLL Study Group

Completed

Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany
French Innovative Leukemia Organisation

Completed

Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia (RemodelWM3)

Waldenstrom Macroglobulinemia

France
AbbVie

Active, not recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

Japan
Swiss Group for Clinical Cancer Research

Completed

Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Follicular Lymphoma

Switzerland
Genentech, Inc.

Completed

An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
Genentech, Inc.; Kite, A Gilead Company

Recruiting

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

B Cell Lymphoma

United States
Abramson Cancer Center at Penn Medicine
Genentech, Inc.

Recruiting

CAR-T Followed by Bispecific Antibodies

DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma

United States
SOTIO Biotech AG
SOTIO Biotech a.s.

Active, not recruiting

Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Mesothelioma | Bladder Cancer | Triple Negative Breast Cancer | Small-cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Thyroid | Anal Cancer | Merkel Cell Carcinoma | Biliary... and other conditions

United States, France, Spain, Czechia
Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital; BeiGene USA, Inc.; Roche-Genentech

Recruiting

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Leukemia (SLL)

United States
German CLL Study Group
Hoffmann-La Roche; Janssen-Cilag Ltd.

Completed

Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients

Chronic Lymphocytic Leucemia

Germany
German CLL Study Group
AbbVie; Hoffmann-La Roche

Active, not recruiting

Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)

Chronic Lymphocytic Leucemia

Germany
University of Wisconsin, Madison
Genentech, Inc.

Terminated

Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma | Non Hodgkin Lymphoma | Non-hodgkin Lymphoma

United States
Institute of Hematology & Blood Diseases Hospital

Recruiting

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

Marginal Zone Lymphoma

China
Genentech, Inc.
Roche Pharma AG

Completed

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

Non-Hodgkin's Lymphoma

United States, Spain, France, Canada, United Kingdom, Austria, Belgium, Czechia, Russian Federation, Italy, Switzerland, Germany, Netherlands, Sweden
Munich Municipal Hospital
German CLL Study Group

Unknown

CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients

Chronic Lymphocytic Leucemia

Germany
Gilead Sciences
German CLL Study Group

Completed

Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany
Hoffmann-La Roche

Completed

A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
Johannes Gutenberg University Mainz
Roche Pharma AG; Servier

Completed

GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma

Lymphoma, Non-Hodgkin

Germany
Hoffmann-La Roche

Terminated

A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

B-Cell Chronic Lymphocytic Leukemia

Italy, Spain, Israel, United Kingdom, Latvia

3

Subscribe